Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SIBN - SI-BONE Inc


IEX Last Trade
16.63
0.320   1.924%

Share volume: 209,041
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Surgical and Medical Instrument Manufacturing : -0.56%

PREVIOUS CLOSE
CHG
CHG%

$16.31
0.32
1.96%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
15%
Profitability 0%
Dept financing 12%
Liquidity 75%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
0.42%
1 Month
11.24%
3 Months
23.39%
6 Months
-4.21%
1 Year
-26.95%
2 Year
1.22%
Key data
Stock price
$16.63
P/E Ratio 
-16.96
DAY RANGE
N/A - N/A
EPS 
-$1.00
52 WEEK RANGE
$11.76 - $23.25
52 WEEK CHANGE
-$0.26
MARKET CAP 
692.957 M
YIELD 
N/A
SHARES OUTSTANDING 
41.694 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
1.10
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$289,560
AVERAGE 30 VOLUME 
$333,314
Company detail
CEO: Jeffrey Dunn
Region: US
Website: https://si-bone.com/
Employees: 500
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Surgical and Medical Instrument Manufacturing
Sector: Manufacturing

si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al

Recent news